Torbjörn Gräslund
Royal Institute of Technology
Fusion proteinBiophysicsProtein engineeringMolecular biologyReceptorAffinity chromatographyChemistryPhage displayConjugateIn vitroIn vivoCombinatorial chemistryBinding domainBiodistributionDrugNeonatal Fc receptorInsulin-like growth factorAffibody moleculeMoleculeChromatographyCancer researchBiochemistryComputational biologyBiologyCell biologyPharmacology
70Publications
21H-index
1,243Citations
Publications 69
Newest
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
Source
#1Tianqi XuH-Index: 2
#2Haozhong DingH-Index: 3
Last. Torbjörn GräslundH-Index: 21
view all 7 authors...
The human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in a variety of cancers and therapies targeting HER2 are routinely used in the clinic. Recently, small engineered scaffold proteins, such as affibody molecules, have shown promise as carriers of cytotoxic drugs, and these drug conjugates may become complements or alternatives to the current HER2-targeting therapies. Here, we investigated if a monovalent HER2-binding affibody molecule, ZHER2:2891, fused with a plasma ...
1 CitationsSource
#1Haozhong Ding (KTH: Royal Institute of Technology)H-Index: 3
#2Mohamed Altai (Lund University)H-Index: 19
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 11 authors...
The human epidermal growth factor receptor 2 (HER2) is a clinically validated target for cancer therapy, and targeted therapies are often used in regimens for patients with a high HER2 expression level. Despite the success of current drugs, a number of patients succumb to their disease, which motivates development of novel drugs with other modes of action. We have previously shown that an albumin binding domain-derived affinity protein with specific affinity for HER2, ADAPT6, can be used to deli...
Source
#1Sergey M. Deyev (Tomsk Polytechnic University)H-Index: 27
#2Anzhelika Vorobyeva (Tomsk Polytechnic University)H-Index: 10
Last. Vladimir Tolmachev (Tomsk Polytechnic University)H-Index: 60
view all 11 authors...
Abstract Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast...
6 CitationsSource
#1Haozhong Ding (KTH: Royal Institute of Technology)H-Index: 3
#2Mohamed Altai (Uppsala University)H-Index: 19
Last. Anna Orlova (Uppsala University)H-Index: 53
view all 7 authors...
Affibody molecules are small affinity-engineered scaffold proteins which can be engineered to bind to desired targets. The therapeutic potential of using an affibody molecule targeting HER2, fused to an albumin-binding domain (ABD) and conjugated with the cytotoxic maytansine derivate MC-DM1 (AffiDC), has been validated. Biodistribution studies in mice revealed an elevated hepatic uptake of the AffiDC, but histopathological examination of livers showed no major signs of toxicity. However, previo...
3 CitationsSource
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 21
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 9 authors...
Potent and specific fusion toxins consisting of a HER2-binding ABD-derived affinity protein (ADAPT), fused to truncated versions of Pseudomonas exotoxin A
5 CitationsSource
#1Shengze Yu (KTH: Royal Institute of Technology)H-Index: 4
#2Amira Alkharusi (Sultan Qaboos University)H-Index: 6
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 4 authors...
: Increasing evidence suggests that signaling through the prolactin/prolactin receptor axis is important for stimulation the growth of many cancers including glioblastoma multiforme, breast and ovarian carcinoma. Efficient inhibitors of signaling have previously been developed but their applicability as cancer drugs is limited by the short in vivo half-life. In this study, we show that a fusion protein, consisting of the prolactin receptor antagonist PrlRA and an albumin binding domain for half-...
4 CitationsSource
Evaluation Of Several Newly Designed Affibody-based Drug Conjugates Using Radionuclide-based Techniques : A Powerful Tool For Drug Development
#1Mohamed Altai (Uppsala University)H-Index: 19
#2Hao Liu (KTH: Royal Institute of Technology)H-Index: 21
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 8 authors...
Abstract Patients with HER2-positive tumors often suffer resistance to therapy, warranting development of novel treatment modalities. Affibody molecules are small affinity proteins which can be engineered to bind to desired targets. They have in recent years been found to allow precise targeting of cancer specific molecular signatures such as the HER2 receptor. In this study, we have investigated the potential of an affibody molecule targeting HER2, ZHER2:2891, conjugated with the cytotoxic mayt...
17 CitationsSource